With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more ...

Sunday on PBS News Weekend, three years after the end of Roe v. Wade, a decades-old movement is exploring new ways to circumvent abortion bans and restrictions. A former FDA head discusses the science ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with sustained ...

McCormick & Company, Incorporated (NYSE:MKC) is one of the Jim Cramer Warns Viewers About FOMO & Discusses These 19 Stocks.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

One of the main researchers, Professor Tore Bengtsson from Stockholm University, said this could be an exciting step forward.

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

A knock-on effect from the use Ozempic is a change of diet, including a reliance on caffeine and low carbs. However, this ...